Language Selection

Get healthy now with MedBeds!
Click here to book your session

Protect your whole family with Orgo-Life® Quantum MedBed Energy Technology® devices.

Advertising by Adpathway

         

 Advertising by Adpathway

Most First Recurrences After Liver Cancer Resection Are Non-Curable, Study Finds

2 hours ago 7

PROTECT YOUR DNA WITH QUANTUM TECHNOLOGY

Orgo-Life the new way to the future

  Advertising by Adpathway

A retrospective clinical investigation conducted at University Hospital Essen has revealed that the majority of initial cancer recurrences following curative-intent surgical resection for hepatocellular carcinoma cannot be salvaged with curative therapies. Hepatocellular carcinoma represents the sixth most commonly diagnosed cancer worldwide and stands as the third leading cause of cancer-related mortality, accounting for the large majority of primary liver malignancies. Although surgical resection remains a cornerstone of curative treatment in carefully selected patients exhibiting preserved hepatic function and resectable tumor burden, long-term postoperative trajectories differ considerably across clinical cohorts. Recurrence following surgery remains a frequent obstacle to durable cancer control, with historical series documenting five-year recurrence rates approaching seventy percent. While recurrence-free survival has conventionally served as an established oncological benchmark, it treats all recurrent disease events identically, conflating solitary treatable lesions with widespread systemic dissemination. The newly reported findings indicate that the clinical amenability of the very first recurrent event serves as a decisive determinant of ultimate patient prognosis.

The study cohort comprised 324 consecutive patients who underwent curative-intent liver resection for hepatocellular carcinoma between 2009 and 2024. Among the broader surgical cohort, the median age at primary intervention was 67 years, with male patients constituting 73.5 percent of the population and a median body mass index recorded at 27 kilograms per square meter. Solitary tumor lesions were identified preoperatively in 81.5 percent of individuals, with a overall median largest tumor diameter measuring 57 millimeters. Macrovascular invasion was identified in 15.8 percent of surgical cases, while portal vein invasion and portal vein thrombosis were noted in 11.6 percent and 6.3 percent, respectively. Complete microscopic clearance with negative resection margins was successfully achieved in 87.5 percent of patients. Across the entire surgical collective, median overall survival spanned 37 months, while median recurrence-free survival lasted 14 months, highlighting the aggressive underlying biological characteristics that frequently govern liver cancer progression.

Over the course of postoperative follow-up, disease recurrence was documented in 169 patients, representing 52.2 percent of the initial surgical cohort. These relapsing patients constituted the primary focus of the recurrence-directed comparative analyses, wherein clinical status was evaluated strictly using clinicopathological parameters recorded at the time of the initial hepatectomy. First recurrence presentations were retrospectively categorized as curatively treatable or noncuratively treatable based on multidisciplinary tumor board assessments and actual therapeutic interventions executed. Curatively treatable recurrence was formally defined as disease managed with curative therapeutic intent, encompassing repeat surgical resection, salvage liver transplantation, or targeted local ablation techniques. Conversely, noncuratively treatable recurrence was established when curative interventions were deemed technically or oncologically unfeasible, necessitating palliative locoregional procedures, systemic pharmacological treatments, or best supportive care measures.

Among the 169 patients with documented and fully characterized first recurrence, only 63 individuals, or 37.3 percent, presented with recurrent disease that remained amenable to curative-intent interventions. In stark contrast, 106 patients, representing 62.7 percent of the recurrent collective, developed initial recurrences that were deemed entirely noncurative. Multidisciplinary review identified multiple distinct clinical reasons preventing curative management among these 106 patients: distant extrahepatic metastatic spread occurred in 40 individuals, accounting for 37.7 percent; extensive multifocal intrahepatic recurrence developed in 32 patients, representing 30.2 percent; severe underlying hepatic impairment precluded aggressive local therapy in 22 patients, or 20.8 percent; and patient-related clinical contraindications barred curative intervention in 12 individuals, comprising 11.3 percent of the noncurative group.

Comparative evaluations of baseline tumor characteristics established marked differences between the two recurrence cohorts dating back to their initial operative encounters. Patients who subsequently suffered noncurative first relapses presented with significantly larger baseline tumors, displaying a median largest nodule diameter of 69 millimeters compared to 55 millimeters among those who developed curatively manageable recurrence. In addition, baseline portal vein thrombosis was documented in 9.8 percent of the noncurative subgroup while being completely absent in the curative cohort. Incomplete microscopic tumor resection, classified as an R1 margin status, occurred in 19 percent of the noncurative cohort compared to 6.5 percent among patients who experienced curative relapse. Preoperative systemic inflammatory markers also differed, with median C-reactive protein levels registering significantly higher in the noncurative recurrence group at 0.6 milligrams per deciliter versus 0.5 milligrams per deciliter in the curative recurrence cohort.

The oncological consequences stemming from recurrence treatability manifested as a dramatic disparity in survival outcomes after disease relapse. While patients experiencing curatively treatable first recurrence attained a median postrecurrence survival of 78 months, those developing noncurative first recurrence experienced a median postrecurrence survival of only 22 months, a gap confirming profound clinical divergence. In univariable Cox proportional hazards modeling, noncurative relapse was linked to a more than threefold increase in the hazard of mortality. Multivariable Cox regression analysis incorporating 144 complete cases and 87 observed deaths demonstrated that noncurative first recurrence remained an independent determinant of compromised postrecurrence survival, conferring a hazard ratio of 3.51. The requirement for intraoperative packed red blood cell transfusion during the primary resection also emerged as an independent predictor of adverse postrecurrence survival, carrying an adjusted hazard ratio of 3.01.

To evaluate the temporal dynamics governing postoperative relapse patterns, investigators performed competing-risk analyses treating death without prior recurrence as an explicit competing event. Throughout post-hepatectomy follow-up, the cumulative incidence of noncurative first recurrence consistently surpassed that of curative relapse across every evaluated milestone. At one year following resection, cumulative incidence rates were 20.8 percent for noncurative recurrence versus 8.8 percent for curative recurrence. By two years, cumulative incidences reached 27.4 percent versus 13.2 percent, rising to 31.1 percent versus 18.0 percent at three years, and culminating at 33.5 percent versus 20.9 percent at five years. Corresponding cumulative mortality rates without preceding recurrence were recorded at 15.7 percent, 17.4 percent, 17.4 percent, and 19.0 percent across the respective annual intervals, demonstrating that noncurative oncological failure accumulates earlier and with greater frequency than salvageable relapse.

To overcome selection biases associated with assessing post-surgical events from the initial date of operation, the researchers carried out an exploratory twelve-month landmark survival analysis. Evaluating 239 patients who remained alive and under observation at one year post-hepatectomy, the landmark model categorized individuals by their recurrence status at that precise juncture. Relative to recurrence-free participants, patients who had experienced curatively treatable relapse within the first twelve months exhibited an adjusted hazard ratio for subsequent mortality of 2.27, whereas those who suffered noncurative relapse demonstrated an adjusted hazard ratio of 6.85. Incorporating recurrence amenability significantly enhanced predictive model fit over binary recurrence classification alone, although gains in Harrell’s concordance index remained modest, advancing from 0.675 to 0.689.

Efforts to construct robust predictive models for noncurative relapse using baseline clinicopathological variables yielded restricted statistical utility. Binary logistic regression identified elevated preoperative C-reactive protein above 0.5 milligrams per deciliter as an independent associate of noncurative relapse with an adjusted odds ratio of 2.13. However, sensitivity analyses demonstrated that when C-reactive protein was modeled as a continuous parameter, its association was not statistically significant. Furthermore, discrimination remained modest, yielding an area under the receiver operating characteristic curve of 0.639 and an optimism-corrected bootstrap value of 0.616. Baseline histological characteristics from primary resections, including tumor differentiation grading, vascular invasion, and lymphatic invasion, showed no statistically significant differences between recurrence groups, underscoring the challenge of anticipating recurrence salvageability through standard preoperative metrics alone.

The study authors emphasize important methodological boundaries inherent to their single-center retrospective study design, including the potential for unmeasured confounding and missing clinical parameters that necessitated complete-case modeling. Because classification of recurrence treatability relied on multidisciplinary clinical evaluations weighing functional hepatic reserve, anatomical feasibility, and underlying patient status, the observed survival gaps are inherently susceptible to confounding by indication rather than establishing a direct causal effect of treatment intent. The researchers conclude that traditional recurrence-free survival overlooks critical distinctions regarding recurrence quality, advocating that clinical treatability at first relapse represents a meaningful complementary endpoint for postoperative surveillance protocols and surgical clinical trials.

Subject of Research: Oncological outcomes and clinical determinants of curative versus noncurative first recurrence after liver resection for hepatocellular carcinoma

Article Title: Curative Versus Non‐Curative First Recurrence After Surgical Resection for Hepatocellular Carcinoma: Determinants, Patterns, and Clinical Impact

Article References: Mantas, A., Lueong, S. S., Dropmann, M., Starck, A., Hoyer, D. P., Schmitz, S. M., Heise, D., Ulmer, T. F., Siveke, J., Neumann, U. P., & Bednarsch, J. (2026). Curative Versus Non‐Curative First Recurrence After Surgical Resection for Hepatocellular Carcinoma: Determinants, Patterns, and Clinical Impact. Cancer Reports, 9(11), Article e70768. https://doi.org/10.1002/cnr2.70768

Image Credits: AI Generated

DOI: 10.1002/cnr2.70768

Keywords: hepatocellular carcinoma, liver resection, cancer recurrence, postrecurrence survival, curative recurrence, noncurative recurrence, competing risk analysis, oncology, liver cancer, surgical oncology, C-reactive protein, landmark analysis, blood transfusion, recurrence patterns, salvage therapy, hepatectomy

Read Entire Article

         

        

Start the new Vibrations with a Medbed Franchise today!  

Protect your whole family with Quantum Orgo-Life® devices

  Advertising by Adpathway